NTRK1 and cancer: Focusing on the insulin growth factor 1 receptor (IGF1R), a receptor tyrosine kinase that mediates growth factor signaling in various tissues and cancers, ZNRF3*IGF1R bispecific antibodies showed clearance up to 80% with specificity for CRC both in vitro and in vivo.